Beaver Davinia, Limnios Ioannis Jason
Clem Jones Centre for Regenerative Medicine, Bond University, Gold Coast, QL, Australia.
Front Transplant. 2023 Sep 29;2:1130086. doi: 10.3389/frtra.2023.1130086. eCollection 2023.
Stem cell therapies can potentially treat various retinal degenerative diseases, including age-related macular degeneration (AMD) and inherited retinal diseases like retinitis pigmentosa. For these diseases, transplanted cells may include stem cell-derived retinal pigmented epithelial (RPE) cells, photoreceptors, or a combination of both. Although stem cell-derived RPE cells have progressed to human clinical trials, therapies using photoreceptors and other retinal cell types are lagging. In this review, we discuss the potential use of human pluripotent stem cell (hPSC)-derived photoreceptors for the treatment of retinal degeneration and highlight the progress and challenges for their efficient production and clinical application in regenerative medicine.
干细胞疗法有可能治疗各种视网膜退行性疾病，包括年龄相关性黄斑变性（AMD）和诸如色素性视网膜炎等遗传性视网膜疾病。对于这些疾病，移植的细胞可能包括干细胞衍生的视网膜色素上皮（RPE）细胞、光感受器或两者的组合。尽管干细胞衍生的RPE细胞已进入人体临床试验阶段，但使用光感受器和其他视网膜细胞类型的疗法仍滞后。在本综述中，我们讨论了人类多能干细胞（hPSC）衍生的光感受器在治疗视网膜变性方面的潜在用途，并强调了其在再生医学中高效生产和临床应用的进展与挑战。
